Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2023 · 12 citations · 19 references
MedicineCancer BiologyOncologyMolecular OncologyNeuro-oncologyTumor ProgressionBrain TumorsCancer BiomarkersCancer GenomicsCancer ProgressionGlioblastomaMalignant NeoplasmsGlioblastoma InvasionGlioblastoma PrognosisGlioblastoma Tumor BiologyImmunohistochemical MarkersImmunohistochemical StainingMuscarinic Acetylcholine Receptor SignalingOncogenic DysregulationTranscriptome Analysis
Glioblastoma (GBM) is the most aggressive cancer of the brain and has a high mortality rate due to the lack of effective treatment strategy. Clarification of molecular mechanisms of GBM’s characteristic invasive growth are urgently needed to improve the poor prognosis. Single-nuclear sequencing of primary and recurrent GBM samples revealed that levels of M3 muscarinic acetylcholine receptor (CHRM3) were significantly higher in the recurrent samples than in the primary samples. Moreover, immunohistochemical staining of an array of GBM samples showed that high levels of CHRM3 correlated with poor prognosis, consistent with The Cancer Genome Atlas database. Knockdown of CHRM3 inhibited GBM cell growth and invasion. An assay of orthotopic GBM animal model in vivo indicated that inhibition of CHRM3 significantly suppressed GBM progression with prolonged survival time. Transcriptome analysis revealed that CHRM3 knockdown significantly reduced an array of classic factors involved in cancer invasive growth, including MMP1/MMP3/MMP10/MMP12 and CXCL1/CXCL5/CXCL8. Taken together, CHRM3 is a novel and vital factor of GBM progression via regulation of multiple oncogenic genes and may serve as a new biomarker for prognosis and therapy of GBM patients.
19
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling
Yoku Hayakawa, Kosuke Sakitani, Mitsuru Konishi et al. · Cancer Cell · 2016 · 549 citations